DS Stage I Plasma Cell Myeloma
Information
- Disease name
- DS Stage I Plasma Cell Myeloma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01668719 | Active, not recruiting | Phase 1/Phase 2 | S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma | November 2012 | June 2024 |
| NCT00445692 | Completed | Phase 2 | Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma | January 10, 2007 | April 24, 2017 |
| NCT00839956 | Completed | Phase 2 | Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant | February 2009 | March 31, 2017 |
| NCT00869206 | Completed | Phase 3 | Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement | March 2009 | January 2017 |
| NCT01330173 | Completed | Phase 1 | Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma | December 2010 | November 2014 |
| NCT01605032 | Completed | Phase 2 | Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma | February 2012 | March 2018 |
| NCT01936090 | Completed | Phase 1 | Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma | August 2013 | February 16, 2018 |
| NCT00088855 | Completed | Phase 2 | Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma | June 15, 2004 | January 8, 2008 |
| NCT01842308 | Completed | Phase 1/Phase 2 | Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma | June 4, 2013 | October 28, 2019 |
| NCT01251172 | Withdrawn | Phase 2 | RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | December 2010 |